Jeffrey CPA - Rallybio Corp CFO CoFounder

RLYB Stock  USD 1.05  0.03  2.94%   

Insider

Jeffrey CPA is CFO CoFounder of Rallybio Corp
Age 54
Phone203 859 3820
Webhttps://www.rallybio.com

Rallybio Corp Management Efficiency

The company has return on total asset (ROA) of (0.3854) % which means that it has lost $0.3854 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6739) %, meaning that it created substantial loss on money invested by shareholders. Rallybio Corp's management efficiency ratios could be used to measure how well Rallybio Corp manages its routine affairs as well as how well it operates its assets and liabilities.
Rallybio Corp currently holds 392 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Rallybio Corp has a current ratio of 20.78, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Rallybio Corp's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Jeffrey TrigilioCullinan Oncology LLC
40
Alan RussellEdgewise Therapeutics
54
MBA MDEliem Therapeutics
63
Silvia BuonamiciMonte Rosa Therapeutics
N/A
Filip MDMonte Rosa Therapeutics
50
Edward MDThird Harmonic Bio
51
Jason CPAMediciNova
46
Kelly SchickC4 Therapeutics
44
John CPAMediciNova
N/A
Arnold LevinePmv Pharmaceuticals
84
Behrad DerakhshanEdgewise Therapeutics
44
Wim SouverijnsPharvaris BV
53
Andreas EMBAMolecular Partners AG
58
Morgan ConnPharvaris BV
55
Patrick AmstutzMolecular Partners AG
49
Jennifer CormierPepGen
N/A
Lauren WhiteC4 Therapeutics
N/A
Dr MBAMediciNova
59
Yuichi MDMediciNova
74
Jo PalmerPhillipsEliem Therapeutics
N/A
Niels SvenstrupPepGen
54
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporaton operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people. Rallybio Corp (RLYB) is traded on NASDAQ Exchange in USA. It is located in 234 Church Street, New Haven, CT, United States, 06510 and employs 43 people. Rallybio Corp is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Rallybio Corp Leadership Team

Elected by the shareholders, the Rallybio Corp's board of directors comprises two types of representatives: Rallybio Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rallybio. The board's role is to monitor Rallybio Corp's management team and ensure that shareholders' interests are well served. Rallybio Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rallybio Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ami Bavishi, Head Communications
Jonathan MBA, CFO Treasurer
Martin MacKay, CoFounder Chairman
MD MB, President, CoFounder
Jeffrey CPA, CFO CoFounder
MD FACP, Chief Officer

Rallybio Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rallybio Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Rallybio Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rallybio Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rallybio Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rallybio Corp Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rallybio Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For information on how to trade Rallybio Stock refer to our How to Trade Rallybio Stock guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rallybio Corp. If investors know Rallybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rallybio Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Rallybio Corp is measured differently than its book value, which is the value of Rallybio that is recorded on the company's balance sheet. Investors also form their own opinion of Rallybio Corp's value that differs from its market value or its book value, called intrinsic value, which is Rallybio Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rallybio Corp's market value can be influenced by many factors that don't directly affect Rallybio Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rallybio Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rallybio Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rallybio Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.